Core Viewpoint - Plexus Corp reported strong adjusted earnings per share (EPS) for the second quarter of fiscal 2025, exceeding expectations, but revenues slightly missed estimates due to mixed performance across sectors [1][2]. Financial Performance - Adjusted EPS for Q2 fiscal 2025 was $1.66, up from $1.19 in the same quarter last year, surpassing the Zacks Consensus Estimate of $1.54 [1]. - Revenues reached $980.2 million, a 1.4% year-over-year increase, but fell short of the Zacks Consensus Estimate of $980.5 million [2]. - Gross profit on a GAAP basis increased 11% year over year to $97.8 million, with a gross margin of 10%, up from 9.1% [6]. Revenue Breakdown - Healthcare/Life Sciences revenues rose 8.4% year over year to $411 million, contributing 42% to total revenues [5]. - Industrial sector revenues decreased 5% year over year to $397 million, accounting for 40% of total revenues [4]. - Revenues from Asia-Pacific increased by 12.5% to $587 million, while EMEA sales declined by 32% [2]. Operational Highlights - Plexus secured 42 manufacturing program wins in the quarter, expected to generate $205 million in annualized revenues once fully ramped [3]. - Selling and administrative expenses rose 3% year over year to $49 million, while adjusted operating margin expanded by 80 basis points to 5.7% [8]. Balance Sheet and Cash Flow - As of March 29, 2025, cash and cash equivalents were $310.5 million, down from $317.2 million as of December 28, 2024 [9]. - Free cash flow for the quarter was reported at $16.5 million [9]. Share Repurchase and Future Outlook - The company repurchased $12.2 million of shares at an average price of $141.18, with $25 million remaining under its $50 million buyback authorization [10]. - For Q3 fiscal 2025, revenues are anticipated to be between $1 billion and $1.04 billion, with non-GAAP EPS expected in the range of $1.65-$1.80 [11].